American Bio Medica Corporation

Equities

ABMC

US0246001087

Medical Equipment, Supplies & Distribution

Market Closed - OTC Markets Other stock markets 10:52:56 2024-05-14 am EDT			5-day change	1st Jan Change
0.0003 ^USD	-85.00%		-85.00%	+200.00%

2023	American Bio Medica Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
2023	American Bio Medica Corporation Auditor Raises 'Going Concern' Doubt	CI

American Bio Medica Corporation announced that it expects to receive $0.125 million in funding from Lincoln Park Capital, LLC

December 09, 2020

American Bio Medica Corporation announced a private placement of 500,000 common shares at a price of $0.25 per share for gross proceeds of $125,000 on December 10, 2022. The company has entered into purchase agreement with Lincoln Park Capital Fund, LLC, a fund managed by Lincoln Park Capital, LLC.

Latest news about American Bio Medica Corporation

American Bio Medica Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-06-12	CI
American Bio Medica Corporation Auditor Raises 'Going Concern' Doubt	23-03-20	CI
American Bio Medica Corporation Announces Termination of Melissa A. Waterhouse as Principal Financial Officer	23-03-01	CI
American Bio Medica Corporation Announces Termination of Melissa A. Waterhouse as Chief Executive Officer	23-03-01	CI
Healgen Scientific LLC completed the acquisition of substantially all of the operating assets of American Bio Medica Corporation.	23-02-27	CI
Healgen Scientific LLC agreed to acquire substantially all of the operating assets of American Bio Medica Corporation for $3 million.	22-12-20	CI
American Bio Medica Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-16	CI
American Bio Medica Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
American Bio Medica Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
American Bio Medica Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-15	CI
American Bio Medica Corporation Auditor Raises 'Going Concern' Doubt	22-04-14	CI
American Bio Medica Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-18	CI
American Bio Medica Corporation announced that it has received $0.1 million in funding	21-10-17	CI
Declaration of Voting Results by American Bio	21-06-29	CI
John J. Moroney Engages in Discussions with American Bio Medica	21-06-01	CI
American Bio Medica Corporation Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-20	CI
Earnings Flash (ABMC) AMERICAN BIO MEDICA CORPORATION Reports Q1 Loss $-0.01	21-05-20	MT
American Bio Medica Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2020	21-04-15	CI
American Bio Medica Corporation Announces Resignation of Chaim Davis from the Board of Directors	21-02-11	CI
American Bio Medica Corporation announced that it expects to receive $0.125 million in funding from Lincoln Park Capital, LLC	20-12-09	CI
American Bio Medica Corporation Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-16	CI
American Bio Medica : Earnings Flash (ABMC) AMERICAN BIO MEDICA CORPORATION Posts Q3 EPS $-0.01	20-11-16	MT
American Bio Medica Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-09-15	CI
American Bio Medica Corporation Reports Earnings Results for the First Quarter Ended March 31, 2020	20-07-31	CI
American Bio Medica Corporation Reports Earnings Results for the Full Year Ended December 31, 2019	20-06-26	CI

Chart American Bio Medica Corporation

Duration

Period

More charts

Company Profile

American Bio Medica Corporation is engaged in the manufacturing and distribution of lateral flow immunoassay tests, primarily for the immediate detection of drugs in urine and oral fluid. The Company also distributes a number of other products related to the immediate detection of drugs and alcohol. It manufactures a number of products that detect the presence or absence of drugs in urine. It manufactures the various urine drug testing product lines, including The Rapid Drug Screen (RDS), RDS InCup, Rapid TOX, Rapid TOX Cup and Private Label Products. RDS is a patented rapid drug test that detects the presence or absence of 2-10 drugs simultaneously in a single urine specimen. RDS InCup is a drug-testing cup that detects the presence or absence of 1-12 drugs in a urine specimen. Its OralStat is a drug test for the detection of drugs in oral fluids. Its Respiratory Syncytial Virus (RSV) test does detect RSV in both children under the age of six, as well as adults over the age of 60.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Income Statement Evolution

More financial data

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
AMERICAN BIO MEDICA CORPORATION	+200.00%	14.43K
BIOMÉRIEUX	-4.17%	12.18B
DIASORIN S.P.A.	+7.57%	5.96B
LANTHEUS HOLDINGS, INC.	+26.94%	5.45B
AUTOBIO DIAGNOSTICS CO., LTD.	-5.09%	4.34B
10X GENOMICS, INC.	-52.54%	3.18B
ANDON HEALTH CO., LTD.	+14.18%	2.75B
MYRIAD GENETICS, INC.	+32.50%	2.3B
VITROLIFE AB	-5.24%	2.28B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-1.69%	1.92B

Diagnostic & Testing Substances